356 related articles for article (PubMed ID: 27610009)
1. Mitochondrial DNA from hepatocytes as a ligand for TLR9: Drivers of nonalcoholic steatohepatitis?
Handa P; Vemulakonda A; Kowdley KV; Uribe M; Méndez-Sánchez N
World J Gastroenterol; 2016 Aug; 22(31):6965-71. PubMed ID: 27610009
[TBL] [Abstract][Full Text] [Related]
2. Hepatocyte mitochondrial DNA drives nonalcoholic steatohepatitis by activation of TLR9.
Garcia-Martinez I; Santoro N; Chen Y; Hoque R; Ouyang X; Caprio S; Shlomchik MJ; Coffman RL; Candia A; Mehal WZ
J Clin Invest; 2016 Mar; 126(3):859-64. PubMed ID: 26808498
[TBL] [Abstract][Full Text] [Related]
3. TLR9 is up-regulated in human and murine NASH: pivotal role in inflammatory recruitment and cell survival.
Mridha AR; Haczeyni F; Yeh MM; Haigh WG; Ioannou GN; Barn V; Ajamieh H; Adams L; Hamdorf JM; Teoh NC; Farrell GC
Clin Sci (Lond); 2017 Aug; 131(16):2145-2159. PubMed ID: 28687713
[TBL] [Abstract][Full Text] [Related]
4. Toll-like receptor 9 promotes steatohepatitis by induction of interleukin-1beta in mice.
Miura K; Kodama Y; Inokuchi S; Schnabl B; Aoyama T; Ohnishi H; Olefsky JM; Brenner DA; Seki E
Gastroenterology; 2010 Jul; 139(1):323-34.e7. PubMed ID: 20347818
[TBL] [Abstract][Full Text] [Related]
5. Pathophysiology of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis.
Manne V; Handa P; Kowdley KV
Clin Liver Dis; 2018 Feb; 22(1):23-37. PubMed ID: 29128059
[TBL] [Abstract][Full Text] [Related]
6. Pathogenesis of NASH: How Metabolic Complications of Overnutrition Favour Lipotoxicity and Pro-Inflammatory Fatty Liver Disease.
Farrell GC; Haczeyni F; Chitturi S
Adv Exp Med Biol; 2018; 1061():19-44. PubMed ID: 29956204
[TBL] [Abstract][Full Text] [Related]
7. Decoding cell death signals in liver inflammation.
Brenner C; Galluzzi L; Kepp O; Kroemer G
J Hepatol; 2013 Sep; 59(3):583-94. PubMed ID: 23567086
[TBL] [Abstract][Full Text] [Related]
8. The common marmoset as a model for the study of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
Kramer JA; Grindley J; Crowell AM; Makaron L; Kohli R; Kirby M; Mansfield KG; Wachtman LM
Vet Pathol; 2015 Mar; 52(2):404-13. PubMed ID: 24913270
[TBL] [Abstract][Full Text] [Related]
9. Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
Takahashi Y; Fukusato T
World J Gastroenterol; 2014 Nov; 20(42):15539-48. PubMed ID: 25400438
[TBL] [Abstract][Full Text] [Related]
10. Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
Takahashi Y; Sugimoto K; Inui H; Fukusato T
World J Gastroenterol; 2015 Apr; 21(13):3777-85. PubMed ID: 25852263
[TBL] [Abstract][Full Text] [Related]
11. Pattern recognition receptors in the development of nonalcoholic fatty liver disease and progression to hepatocellular carcinoma: An emerging therapeutic strategy.
Huang C; Zhou Y; Cheng J; Guo X; Shou D; Quan Y; Chen H; Chen H; Zhou Y
Front Endocrinol (Lausanne); 2023; 14():1145392. PubMed ID: 37020586
[TBL] [Abstract][Full Text] [Related]
12. SLAMF1 is expressed and secreted by hepatocytes and the liver in nonalcoholic fatty liver disease.
Gomez-Torres O; Amatya S; Kamberov L; Dhaibar HA; Khanna P; Rom O; Yurdagul A; Orr AW; Nunez K; Thevenot P; Cohen A; Samant H; Alexander JS; Burgos-Ramos E; Chapa-Rodriguez A; Cruz-Topete D
Am J Physiol Gastrointest Liver Physiol; 2022 Sep; 323(3):G177-G187. PubMed ID: 35853010
[TBL] [Abstract][Full Text] [Related]
13. STING-mediated inflammation in Kupffer cells contributes to progression of nonalcoholic steatohepatitis.
Yu Y; Liu Y; An W; Song J; Zhang Y; Zhao X
J Clin Invest; 2019 Feb; 129(2):546-555. PubMed ID: 30561388
[TBL] [Abstract][Full Text] [Related]
14. Mitochondrial DNA from hepatocytes induces upregulation of interleukin-33 expression of macrophages in nonalcoholic steatohepatitis.
Gao Y; Wang Y; Liu H; Liu Z; Zhao J
Dig Liver Dis; 2020 Jun; 52(6):637-643. PubMed ID: 32360132
[TBL] [Abstract][Full Text] [Related]
15. Pathogenesis of Nonalcoholic Steatohepatitis.
Machado MV; Diehl AM
Gastroenterology; 2016 Jun; 150(8):1769-77. PubMed ID: 26928243
[TBL] [Abstract][Full Text] [Related]
16. The Role of Innate Immune Cells in Nonalcoholic Steatohepatitis.
Cai J; Zhang XJ; Li H
Hepatology; 2019 Sep; 70(3):1026-1037. PubMed ID: 30653691
[TBL] [Abstract][Full Text] [Related]
17. Innate Immunity and Inflammation in NAFLD/NASH.
Arrese M; Cabrera D; Kalergis AM; Feldstein AE
Dig Dis Sci; 2016 May; 61(5):1294-303. PubMed ID: 26841783
[TBL] [Abstract][Full Text] [Related]
18. Roles of Hepatic Innate and Innate-Like Lymphocytes in Nonalcoholic Steatohepatitis.
Chen Y; Tian Z
Front Immunol; 2020; 11():1500. PubMed ID: 32765518
[TBL] [Abstract][Full Text] [Related]
19. The role of hepatic macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
Cha JY; Kim DH; Chun KH
Lab Anim Res; 2018 Dec; 34(4):133-139. PubMed ID: 30671098
[TBL] [Abstract][Full Text] [Related]
20. The role of macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
Kazankov K; Jørgensen SMD; Thomsen KL; Møller HJ; Vilstrup H; George J; Schuppan D; Grønbæk H
Nat Rev Gastroenterol Hepatol; 2019 Mar; 16(3):145-159. PubMed ID: 30482910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
